<?xml version="1.0" encoding="UTF-8"?><BillSummaries>
    <item congress="118" measure-type="hr" measure-number="7188" measure-id="id118hr7188" originChamber="HOUSE" orig-publish-date="2024-02-01" update-date="2024-12-17">
        <title>Shandra Eisenga Human Cell and Tissue Product Safety Act</title>
        <summary summary-id="id118hr7188v07" currentChamber="HOUSE" update-date="2024-12-17">
            <action-date>2024-11-22</action-date>
            <action-desc>Reported to House</action-desc>
            <summary-text><![CDATA[<p><strong>Shandra Eisenga Human Cell and Tissue Product Safety Act</strong></p><p>This bill requires federal agencies to update guidance, regulations, and educational materials about transplants involving human cell and tissue products, particularly with respect to safety and eligibility standards.</p><p>Specifically, the Department of Health and Human Services must support the development of educational materials for health care providers about issues relating to organ, tissue, and eye donations; screening tests; and other aspects of donations. The Food and Drug Administration (FDA) must review current guidance on donor eligibility and, if appropriate, update it with information on how to reduce the spread of tuberculosis or sepsis in association with donations. The FDA must also publish information about&nbsp;its Tissue Reference Group and data about FDA inspections and registrations of human cell and tissue establishments. </p><p>The bill also establishes specific civil penalties for violations of regulations governing procedures for human cell and&nbsp;tissue products. The FDA must consider and recommend ways to update these regulations after a public comment period.<br/></p>]]></summary-text>
        </summary>
        <summary summary-id="id118hr7188v00" currentChamber="HOUSE" update-date="2024-12-11">
            <action-date>2024-02-01</action-date>
            <action-desc>Introduced in House</action-desc>
            <summary-text><![CDATA[<p><strong>Shandra Eisenga Human Cell and Tissue Product Safety Act</strong></p><p>This bill requires the Department of Health and Human Services (HHS) to educate the public and health care providers about the benefits and risks of transplants that use human cell or tissue products, including the risk of infections.</p><p>HHS must develop the educational campaign after taking into consideration information about products that carry the highest risk of transmitting infections to transplant recipients. HHS may award grants to other entities to conduct public awareness initiatives and media campaigns about the risk of infections.&nbsp;</p><p>The bill also establishes specific civil penalties for violations of laws regarding the spread of communicable diseases and regulations regarding procedures for human cell or tissue products.</p>]]></summary-text>
        </summary>
    </item>
    <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
        <dc:format>text/xml</dc:format>
        <dc:language>EN</dc:language>
        <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
        <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
        <dc:description>This file contains bill summaries for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
    </dublinCore>
</BillSummaries>
